About this trial

This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.

Eligibility criteria

Qualifiers

Cohort A: Breast Malignancy

Cohort B: Gynecological Malignancy

Cohort C: Head and Neck Malignancies

Cohort D: Sarcomas

Disqualifiers

Medical comorbidities precluding locally ablative therapies.

History of treatment related toxicities that limit or prohibit application of locally ablative therapies.

Progressing intracranial lesions.

Trial design

Treatments tested in this trial

  • Ablative local therapy

Treatment groups

250 Participants
are divided into 1 treatment group

Locations

1
University of California, Davis95817, SacramentoCalifornia, United States

Sponsors and collaborators

University of California, Davis

Lead sponsor

National Cancer Institute (NCI)

Collaborator